Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622001381774
Ethics application status
Approved
Date submitted
20/10/2022
Date registered
28/10/2022
Date last updated
23/06/2024
Date data sharing statement initially provided
28/10/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
The Momentum Program: Online Cognitive Behavioural Therapy (CBT) for Adolescent Anxiety and Depression Comorbidity
Scientific title
Efficacy of Online CBT for Adolescent Anxiety and Depression Comorbidity on Symptom Severity: A Randomised Controlled Trial of the Momentum Program
Secondary ID [1] 308222 0
None
Universal Trial Number (UTN)
U1111-1283-9970
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anxiety 327947 0
Depression 327948 0
Condition category
Condition code
Mental Health 325013 325013 0 0
Anxiety
Mental Health 325014 325014 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The design involves a two-arm parallel-group RCT where adolescents aged 13-17 years with comorbid anxiety and depression will be randomly assigned to either the online comorbid (COM) program condition targeting comorbid anxiety and depression, or the online primary diagnosis (PRI) program condition targeting the primary presenting problem (anxiety or depression). Both arms (i.e. Intervention Arm 1 and Intervention Arm 2) will receive an online intervention program.

The online programs will be accessed via the Momentum platform (https://momentumhub.org.au). The online interventions on the Momentum platform are self-directed and there is no contact with a therapist or a psychologist. The intervention program will be either 7 (PRI programs) or 10 (COM programs) sessions. The sessions will become available weekly. Each session does not have to be completed in one go, but each session will need to be completed before the participants move on to the next one. The users will receive automated reminders related to session availability. On the home page, the users will be able to monitor how far they are in their assigned program.

The Momentum program sessions have been co-designed with young people to ensure they are engaging and interactive. Sessions include the use of images, interactive elements, pop-up messages, and quizzes that provide immediate feedback. Each session comprises approximately 30 slides and takes an estimated 45 minutes to complete. Number of sessions will change depending on the intervention arms. Homework assignments can be completed online or can be printed out. Each session follows a similar format: (1) Feelings check-in (where the young person completes brief anxiety and depression questionnaires); (2) A review of homework from the previous session; (3) A summary quiz of the previous session; (4) Presentation of the main content of the session (e.g., cognitive restructuring); (5) A quiz to see what they have learned from the session; and (6) Homework activities to be completed over the following week.

Intervention Arm 1- Program targeting comorbidity of anxiety and depression (COM):
There will be TWO versions of comorbid program: one for young people with primary anxiety and one for young people with primary depression. The content of these programs is identical, with only the order of session presentation differing between them. For young people with primary anxiety, the content specific to anxiety will be presented before the content specific to depression. For young people with primary depression, the content specific to depression will be presented before the content specific to anxiety.

Program targeting comorbid anxiety and depression where anxiety is primary (COM-AD):
This program will be provided to those participants with primary anxiety who have been
allocated to the COM arm of the RCT. The COM-AD program involves 10 Cognitive Behavioural Therapy (CBT) sessions. Session 1 focuses on psychoeducation around anxiety AND depression. Sessions 2-4 focus on anxiety-specific skills (i.e., relaxation, avoidance and exposure). Sessions 5-7 focus on depression-specific skills (i.e., behavioural activation and appreciation/gratitude). Sessions 8-9 will focus on cognitive restructuring for anxiety AND depression. Session 10 will focus on relapse prevention for both anxiety AND depression.

Program targeting comorbid anxiety and depression where depression is primary (COM-DA):
This program will be provided to those participants with primary depression who have been allocated to the COM arm of the RCT. The COM-DA program involves 10 CBT sessions. Session 1 focuses on psychoeducation around depression AND anxiety. Sessions 2-4 focus on
depression-specific skills (i.e., behavioural activation and appreciation/gratitude). Sessions 5-7 focus on anxiety-specific skills (i.e., relaxation, avoidance and exposure). Sessions 8-9 will
focus on cognitive restructuring for depression AND anxiety. Session 10 will focus on relapse
prevention for both anxiety AND depression.
Intervention code [1] 324655 0
Treatment: Other
Intervention code [2] 324656 0
Behaviour
Comparator / control treatment
Intervention Arm 2 - Program targeting primary presenting problem (PRI):
There will be two versions of program targeting primary presenting problem: (1) Program targeting primary depression (2) Program targeting primary anxiety.

The Momentum program sessions targeting primary problem have the same format and duration as the sessions targeting comorbidity (as described above). The sessions have been co-designed with young people to ensure they are engaging and interactive. Sessions include the use of images, interactive elements, pop-up messages, and quizzes that provide immediate feedback. Each session comprises approximately 30 slides and takes an estimated 45 minutes to complete. Number of sessions will change depending on the intervention arms. Homework assignments can be completed online or can be printed out. Each session follows a similar format: (1) Feelings check-in (where the young person completes brief anxiety and depression questionnaires); (2) A review of homework from the previous session; (3) A summary quiz of the previous session; (4) Presentation of the main content of the session (e.g., cognitive restructuring); (5) A quiz to see what they have learned from the session; and (6) Homework activities to be completed over the following week.

Program targeting primary depression (PRI-D). This program will be provided to those
participants with primary depression who have been allocated to the PRI arm of the RCT. The PRI-D program involves 7 CBT sessions. Session 1 focuses on psychoeducation around depression. Sessions 2-4 focus on behavioural activation, relaxation and appreciation/gratitude. Sessions 5-6 focus on cognitive restructuring. Session 7 focuses on relapse prevention.

Program targeting primary anxiety (PRI-A). This program will be provided to those participants with primary anxiety who have been allocated to the PRI arm of the RCT. The PRI-A program involves 7 CBT sessions. Session 1 focuses on psychoeducation around anxiety. Sessions 2-4 focus on relaxation, understanding the avoidance cycle and exposure. Sessions 5-6 focus on cognitive restructuring. Session 7 focuses on relapse prevention.
Control group
Active

Outcomes
Primary outcome [1] 332858 0
Youth depressive symptoms

Depressive symptoms will be assessed with the Centre for Epidemiological Studies Depression Scale for adolescents (CES-D; Radloff, 1991).
Timepoint [1] 332858 0
Pre-intervention, 3-month post-baseline (primary endpoint), 9-month post-baseline follow up
Primary outcome [2] 332859 0
Youth anxiety symptoms

Anxiety symptoms will be assessed with the Spence Children’s Anxiety Scale (SCAS; Spence, 1998).
Timepoint [2] 332859 0
Pre-intervention, 3-month post-baseline (primary endpoint) 9-month post-baseline follow up
Secondary outcome [1] 414880 0
Quality of life

Quality of life will be assessed with the Child Health Utility 9 Index (CHU9D; Ratcliffe et al., 2012).
Timepoint [1] 414880 0
Pre-intervention
Post-completion of program
6-month post-baseline follow up
12-month post-baseline follow up
Secondary outcome [2] 414881 0
Treatment satisfaction and acceptability

Treatment satisfaction and acceptability will be assessed at post-intervention with a 6-item questionnaire adapted from March et al. (2009), in which young people are asked to rate their program satisfaction on a 5-point scale.
Timepoint [2] 414881 0
Post-completion of program

Eligibility
Key inclusion criteria
Following registration and the initial assessment process that is part of the open access Momentum Platform, adolescents aged 13-17 years who are found to demonstrate comorbid anxiety and depression symptoms will be invited to participate in the study. Participants must be willing to participate in either of the two conditions (COM or PRI).
Minimum age
13 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Potential participants will be excluded if the adolescent (i) has an intellectual or a developmental disorder (autism, developmental delay); (ii) is receiving other psychological/psychiatric treatment for their primary problem (anxiety or depression); (iii) is not stabilised on a medication prior to enrolment into this study or alters their medication dosage during the trial (if the participant is using medication for anxiety or depression); (iv) displays a high suicidal risk (i.e., a score >21 on the Suicidal Ideation Attributes Scale by Van Spijker et al. (2014)).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be done by central randomisation by the Momentum Platform hosted by GreenAnt Networks secure servers.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Eligible participants will be randomised in a 1:1 ratio to either the COM or PRI condition, using a central, web-based randomisation service hosted by GreenAnt Networks secure servers. Random allocation will occur after stratification by gender and primary problem (i.e. anxiety or depression) for the RCT. Following random allocation to condition, participants will be provided access to and be able to begin their relevant allocated program immediately.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
All variables will be examined for outliers, inter- and intra-measure consistency, normality and for obviously erroneous data. Preliminary analyses will compare groups on demographic and clinical characteristics at baseline using linear (for continuous measures) or logistic (for categorical or severely skewed measures) regression. Due to randomisation, we anticipate no systematic between group differences in data other than that which has been hypothesised. However, if differences are detected we will investigate and report the extent to which the results are altered when these differences are statistically controlled for. To evaluate intervention effects, we will use mixed-effects linear regression to take into account repeated measurements within participants.

The power calculation is based on a 2 (Condition: COM vs PRI) x 2 (Time: pre-assessment and post-intervention) repeated measures design. Considering the participants in both conditions are receiving active intervention programs, we have decided to calculate our sample size based on the small interaction effect (Cohen’s f=0.1). With 80% power and alpha at 0.05, according to a two-tailed hypothesis, we need 100 participants per condition to obtain a small significant interaction effect (200 participants in total). Our planned sample of 270 allows for the potential attrition of 35% of participants (Spence et al., 2017), and the proposed sample size will provide sufficient power to conduct the proposed analyses.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
29/02/2024
Actual
Date of last participant enrolment
Anticipated
1/01/2025
Actual
Date of last data collection
Anticipated
1/09/2025
Actual
Sample size
Target
270
Accrual to date
0
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 312458 0
Government body
Name [1] 312458 0
National Health and Medical Research Council - Medical Research Future Fund (MRFF)
Country [1] 312458 0
Australia
Primary sponsor type
University
Name
Griffith University
Address
176 Messines Ridge Rd.
Mt Gravatt QLD 4122
Country
Australia
Secondary sponsor category [1] 314061 0
University
Name [1] 314061 0
University of Southern Queensland
Address [1] 314061 0
USQ Springfield
37 Sinnathamby Blvd.
Springfield Central
QLD 4300
Country [1] 314061 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 311804 0
Griffith University Human Research Ethics Committee
Ethics committee address [1] 311804 0
Ethics committee country [1] 311804 0
Australia
Date submitted for ethics approval [1] 311804 0
15/09/2022
Approval date [1] 311804 0
22/12/2023
Ethics approval number [1] 311804 0
GU Ref No: 2022/743

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 122422 0
Prof Caroline Donovan
Address 122422 0
School of Applied Psychology
Griffith University
Mt Gravatt Campus
176 Messines Ridge Rd
Mt Gravatt QLD 4122
Country 122422 0
Australia
Phone 122422 0
+61 737353401
Fax 122422 0
Email 122422 0
c.donovan@griffith.edu.au
Contact person for public queries
Name 122423 0
Caroline Donovan
Address 122423 0
School of Applied Psychology
Griffith University
Mt Gravatt Campus
176 Messines Ridge Rd
Mt Gravatt QLD 4122
Country 122423 0
Australia
Phone 122423 0
+61 737353401
Fax 122423 0
Email 122423 0
c.donovan@griffith.edu.au
Contact person for scientific queries
Name 122424 0
Caroline Donovan
Address 122424 0
School of Applied Psychology
Griffith University
Mt Gravatt Campus
176 Messines Ridge Rd
Mt Gravatt QLD 4122
Country 122424 0
Australia
Phone 122424 0
+61 737353401
Fax 122424 0
Email 122424 0
c.donovan@griffith.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified data pertaining to primary and secondary outcomes may be shared. De-identified data will be shared with researchers under circumstances where the researchers have appropriate ethics approvals and appropriate research questions.
When will data be available (start and end dates)?
Data will only become available after all data has been analysed and results published from the trial. This includes both primary research questions, secondary research questions and those arising from the study later. The start and end dates for when the data will or will not be available are to be determined.
Available to whom?
This de-identified data may be available to other researchers who hold suitable ethical clearance and wish to collaborate with the investigator team.
Available for what types of analyses?
The de-identified data may be available for review and meta-analytic purposes or other analyses on request.
How or where can data be obtained?
The data can be obtained from the primary investigator at c.donovan@griffith.edu.au


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
17404Ethical approval  c.donovan@griffith.edu.au
17425Informed consent form  c.donovan@griffith.edu.au



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.